InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss of $0.37

InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q2 EPS of ($0.37), versus ($0.48) reported last year.

"The second quarter of fiscal 2021 saw InMed achieve several key, value-adding and risk mitigating milestones across both its therapeutic programs and IntegraSynTM manufacturing approach," said InMed President and Chief Executive Officer, Eric A. Adams. "We now have a strong body of safety and tolerability data for INM-755, which is the basis for our plans to commence safety and efficacy trials in Epidermolysis Bullosa patients this calendar year. We announced business development activities in both our ocular therapeutic and our innovative, biosynthesis-based IntegraSynTM manufacturing program this last quarter. These announcements are a reflection of our increased emphasis on business development activities as an avenue to advance our R&D efforts."

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.

You May Also Be Interested In

• SLM (SLM) Misses Q2 EPS by 16c; offers guidance
• American Business Bank (AMBZ) Tops Q2 EPS by 177c
• Summit Therapeutics (SMMT) Reports In-Line Q2 EPS